Novo Nordisk announced the appointment of Michael Mawby to the new position of chief government affairs officer. Mawby joins Novo Nordisk from the American Diabetes Association (ADA), where he served as national vice president of government relations and advocacy. At Novo Nordisk, Mawby will influence public policy to improve the treatment, care, and healthcare coverage for people with diabetes. He will be based in the company’s newly opened office at 2401 Pennsylvania Avenue in Washington, DC.

“Michael is an experienced and long-time leader on diabetes policy and legislative issues with the American Diabetes Association,” said Martin Soeters, president of Novo Nordisk Pharmaceuticals, Inc. “Michael’s appointment, combined with the opening of our new office in the capitol, will substantially increase Novo Nordisk’s ability to make its voice heard on healthcare public policy issues.”

Mawby said, “I am delighted to join Novo Nordisk and head its government affairs function. A worldwide leader in diabetes care, Novo Nordisk has a proven patient focus and can bring important resources to the fight to improve healthcare in the United States. I look forward to informing Congress and the executive branch about what Novo Nordisk stands for and to working with patient advocacy groups to improve the lives of people with diabetes.”